EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Minimal Residual Disease Testing for Diffuse Large B Cell Lymphoma

Miral Atout, Hadeel Elwaheidi, Rand Maarouf, Abdulwahab A Albabtain, Saud Alhayli, Alfadel Alshaibani, Mahmoud Aljurf, Riad El Fakih

Clinical Lymphoma Myeloma and Leukemia · 2025-10 · 25 (10) · e750-e755

DOI: 10.1016/j.clml.2025.05.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025-10. Verfasst von Miral Atout und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia. Electronic address: matout@alfaisal.edu. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual, Circulating Tumor DNA. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE OF REVIEW: Diffuse Large B-cell Lymphoma (DLBCL) is challenging to treat in the context of relapsed and refractory disease. Although approximately 65% of patients are cured with frontline chemotherapy, 35% remain refractory or subsequently relapse following frontline therapy, indicating an urgent need for tailored therapies. This review presents how Minimal Residual Disease (MRD) testing, specifically through the analysis of circulating tumor DNA (ctDNA) in blood, serves as a clinical prognostic factor that may predict relapses and aid in treatment decisions. RECENT FINDINGS: We describe multiple MRD detection techniques, including droplet digital polymerase chain reaction (DdPCR) and next-generation sequencing (NGS), emphasizing their importance in understanding patients' responses to treatment and in assessing risk levels. SUMMARY: The analysis of ctDNA could be a promising tool to guide physicians to intervene earlier, possibly improving patient outcomes and quality of life. Nonetheless, standardizing these detection techniques and integrating them into clinical practice remain challenging. Future research is crucial to address these barriers, paving the path for greater use of MRD testing in DLBCL management and improving the delivery of effective treatment to patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseNeoplasm, ResidualCirculating Tumor DNAHumansHigh-Throughput Nucleotide SequencingPrognosis

Stichwörter der Autor:innen

CAPP-SeqCirculating tumor DNA (ctDNA)Next-Generation sequencing (NGS)PhasED-SeqPolymerase chain reaction (PCR)

Substanzen

Circulating Tumor DNA

Autor:innen und Institutionen

  • College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia. Electronic address: matout@alfaisal.edu.
  • College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
  • Department of Hematology, King Faisal Specialist Hospital & Research Center, Riyadh 11564, Saudi Arabia.
  • College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia; Department of Hematology, King Faisal Specialist Hospital & Research Center, Riyadh 11564, Saudi Arabia.

Zitieren

APA

Atout, M., Elwaheidi, H., Maarouf, R., Albabtain, A. A., Alhayli, S., Alshaibani, A., Aljurf, M., & El Fakih, R. (2025). Minimal Residual Disease Testing for Diffuse Large B Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia, 25(10), e750-e755. https://doi.org/10.1016/j.clml.2025.05.003

Vancouver

Atout M, Elwaheidi H, Maarouf R, Albabtain AA, Alhayli S, Alshaibani A, et al. Minimal Residual Disease Testing for Diffuse Large B Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2025;25(10):e750-e755. doi:10.1016/j.clml.2025.05.003

BibTeX
@article{Atout2025,
  author = {Atout, Miral and Elwaheidi, Hadeel and Maarouf, Rand and Albabtain, Abdulwahab A and Alhayli, Saud and Alshaibani, Alfadel and Aljurf, Mahmoud and El Fakih, Riad},
  title = {Minimal Residual Disease Testing for Diffuse Large B Cell Lymphoma},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  volume = {25},
  number = {10},
  pages = {e750--e755},
  doi = {10.1016/j.clml.2025.05.003}
}
Kostenlos starten →